An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
15 août 2023 15h40 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
27 juil. 2023 16h00 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
30 mai 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
18 avr. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
28 févr. 2023 08h00 HE
|
Ad Scientiam
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel...
Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
28 févr. 2023 08h00 HE
|
Ad Scientiam
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel...
Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast period - By PMI
04 juil. 2022 09h45 HE
|
PMI
Covina, July 04, 2022 (GLOBE NEWSWIRE) -- Particularly in the worldwide emerging economies, the Pharmerging industry is growing significantly. Some of the main drivers of this market's expansion are...
Persbericht Biocartis Group NV: Biocartis kondigt nieuwe overeenkomst aan met AstraZeneca voor de ontwikkeling en marketing van een companion diagnostic test voor Tagrisso®
22 juin 2022 01h00 HE
|
Biocartis NV
PERSBERICHT: 22 juni 2022, 07:00 CEST Biocartis kondigt nieuwe overeenkomst aan met AstraZeneca voor de ontwikkeling en marketing van een companion diagnostic test voor Tagrisso® Mechelen, België,...
Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
22 juin 2022 01h00 HE
|
Biocartis NV
PRESS RELEASE: 22 June 2022, 07:00 CEST Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Mechelen, Belgium, 22 June...
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
06 oct. 2021 08h00 HE
|
Fortress Biotech, Inc.
Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 NEW YORK and BORDENTOWN, N.J., Oct. 06, 2021 ...